hydralazine has been researched along with Birth Weight in 19 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although hydralazine has been the drug of choice for treating pregnancy-induced hypertension for some time owing to its effect on peripheral vascular tonus, its effects on utero- and feto-placental circulation are less well understood." | 9.08 | Effects of hydralazine on placental and renal circulation in pre-eclampsia. ( Gennser, G; Gudmundsson, S; Marsal, K, 1995) |
| " Control of hypertension was equivalent in both treatment groups, and in 64 (35%) cases hydralazine had to be added to the treatment to achieve the therapeutic goal (diastolic blood pressure below 85 mm Hg)." | 9.05 | Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. ( Gallery, ED; Gyory, AZ; Ross, MR, 1985) |
| " Cyclic GMP concentrations were also determined in 12 women with severe pre-eclampsia before and after treatment with hydralazine." | 7.69 | Cyclic guanosine 3',5' monophosphate concentrations in pre-eclampsia: effects of hydralazine. ( Calle, A; Jácome, P; López-Jaramillo, P; Narváez, M; Nava, E; Rivera, J; Ruano, C, 1996) |
| "Although hydralazine has been the drug of choice for treating pregnancy-induced hypertension for some time owing to its effect on peripheral vascular tonus, its effects on utero- and feto-placental circulation are less well understood." | 5.08 | Effects of hydralazine on placental and renal circulation in pre-eclampsia. ( Gennser, G; Gudmundsson, S; Marsal, K, 1995) |
| " Control of hypertension was equivalent in both treatment groups, and in 64 (35%) cases hydralazine had to be added to the treatment to achieve the therapeutic goal (diastolic blood pressure below 85 mm Hg)." | 5.05 | Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa. ( Gallery, ED; Gyory, AZ; Ross, MR, 1985) |
| " Cyclic GMP concentrations were also determined in 12 women with severe pre-eclampsia before and after treatment with hydralazine." | 3.69 | Cyclic guanosine 3',5' monophosphate concentrations in pre-eclampsia: effects of hydralazine. ( Calle, A; Jácome, P; López-Jaramillo, P; Narváez, M; Nava, E; Rivera, J; Ruano, C, 1996) |
| "An active approach to the management of severe pre-eclampsia is outlined using sedation with diazepam, hypotensive therapy with hydralazine and immediate steps to terminate the pregnancy." | 3.65 | Active management of severe pre-eclampsia. ( Baskett, TF; Bradford, CR, 1973) |
| "The incidence of preeclampsia in the randomized prophylactic antihypertensive group was statistically lower than that in the nonrandomized group (8." | 2.65 | The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies. ( Crenshaw, MC; Dorminy, JH; Gall, SA; Jelovsek, FR; Welt, SI, 1981) |
| "Neonatal hypertension is increasingly recognized as dramatic improvements in neonatal intensive care, advancements in our understanding of neonatal physiology, and implementation of new therapies have led to improved survival of premature infants." | 2.61 | Neonatal hypertension: cases, causes, and clinical approach. ( Flynn, JT; Starr, MC, 2019) |
| "Pregnancies complicated by severe preeclampsia in the second trimester are associated with a high incidence of perinatal morbidity and mortality." | 1.27 | Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester. ( Abdella, TN; Anderson, GD; Brooks, TF; Sibai, BM; Spinnato, JA; Taslimi, M, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (57.89) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Antza, C | 1 |
| Dimou, C | 1 |
| Doundoulakis, I | 1 |
| Akrivos, E | 1 |
| Stabouli, S | 1 |
| Haidich, AB | 1 |
| Goulis, DG | 1 |
| Kotsis, V | 1 |
| Starr, MC | 1 |
| Flynn, JT | 1 |
| Teran, E | 1 |
| Briones, F | 1 |
| Nicolalde, V | 1 |
| Vivero, S | 1 |
| Chedraui, P | 1 |
| Pérez-López, FR | 1 |
| Sandström, B | 2 |
| Welt, SI | 1 |
| Dorminy, JH | 1 |
| Jelovsek, FR | 1 |
| Crenshaw, MC | 1 |
| Gall, SA | 1 |
| Vink, GJ | 1 |
| Moodley, J | 1 |
| Philpott, RH | 1 |
| Gudmundsson, S | 1 |
| Gennser, G | 1 |
| Marsal, K | 1 |
| Pryde, PG | 1 |
| Abel, EL | 1 |
| Hannigan, J | 1 |
| Evans, MI | 1 |
| Cotton, DB | 1 |
| López-Jaramillo, P | 1 |
| Narváez, M | 1 |
| Calle, A | 1 |
| Rivera, J | 1 |
| Jácome, P | 1 |
| Ruano, C | 1 |
| Nava, E | 1 |
| Curet, LB | 1 |
| Olson, RW | 1 |
| Phippard, AF | 1 |
| Fischer, WE | 1 |
| Horvath, JS | 1 |
| Child, AG | 1 |
| Korda, AR | 1 |
| Henderson-Smart, D | 1 |
| Duggin, GG | 1 |
| Tiller, DJ | 1 |
| Plouin, PF | 1 |
| Breart, G | 1 |
| Llado, J | 1 |
| Dalle, M | 1 |
| Keller, ME | 1 |
| Goujon, H | 1 |
| Berchel, C | 1 |
| Derham, RJ | 1 |
| Hawkins, DF | 1 |
| De Vries, LS | 1 |
| Aber, VR | 1 |
| Elder, MG | 1 |
| Gallery, ED | 1 |
| Ross, MR | 1 |
| Gyory, AZ | 1 |
| Morrison, JC | 1 |
| Whitworth, NS | 1 |
| Bates, GW | 1 |
| McKay, ML | 1 |
| Gookin, KS | 1 |
| Wiser, WL | 1 |
| Friesen, HG | 1 |
| Sibai, BM | 1 |
| Taslimi, M | 1 |
| Abdella, TN | 1 |
| Brooks, TF | 1 |
| Spinnato, JA | 1 |
| Anderson, GD | 1 |
| Eklöf-Slangus, S | 1 |
| Baskett, TF | 1 |
| Bradford, CR | 1 |
2 reviews available for hydralazine and Birth Weight
| Article | Year |
|---|---|
The flipside of hydralazine in pregnancy: A systematic review and meta-analysis.
Topics: Antihypertensive Agents; Birth Weight; Female; Heart Rate; Humans; Hydralazine; Hypertension; Hypert | 2020 |
Neonatal hypertension: cases, causes, and clinical approach.
Topics: Administration, Intravenous; Antihypertensive Agents; Birth Weight; Blood Pressure; Blood Pressure D | 2019 |
5 trials available for hydralazine and Birth Weight
| Article | Year |
|---|---|
The effects of prophylactic management and therapeutics on hypertensive disease in pregnancy: preliminary studies.
Topics: Adult; Antihypertensive Agents; Birth Weight; Blood Pressure; Body Weight; Female; Humans; Hydralazi | 1981 |
Effects of hydralazine on placental and renal circulation in pre-eclampsia.
Topics: Adult; Birth Weight; Blood Circulation; Blood Flow Velocity; Blood Pressure; Drug Evaluation; Female | 1995 |
Early blood pressure control improves pregnancy outcome in primigravid women with mild hypertension.
Topics: Adult; Birth Weight; Blood Pressure; Clonidine; Double-Blind Method; Drug Administration Schedule; D | 1991 |
A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension.
Topics: Adult; Birth Weight; Cesarean Section; Dihydralazine; Double-Blind Method; Drug Therapy, Combination | 1990 |
Antihypertensive treatment in pregnancy: analysis of different responses to oxprenolol and methyldopa.
Topics: Adult; Birth Weight; Clinical Trials as Topic; Female; Humans; Hydralazine; Hypertension; Infant, Ne | 1985 |
12 other studies available for hydralazine and Birth Weight
| Article | Year |
|---|---|
Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study.
Topics: Adolescent; Adult; Antihypertensive Agents; Birth Weight; Blood Pressure; Female; Humans; Hydralazin | 2012 |
Adrenergic beta-receptor blockers in hypertension of pregnancy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Birth Weight; Blood Pressure; Delivery, Obstetric; F | 1982 |
Clinical trials of adrenergic antagonists in pregnancy hypertension.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Apgar Score; Birth Weight; Female; Fetal Growt | 1984 |
Effect of dihydralazine on the fetus in the treatment of maternal hypertension.
Topics: Birth Weight; Dihydralazine; Female; Fetal Death; Fetal Growth Retardation; Fetal Heart; Fetal Monit | 1980 |
Effects of hydralazine on pregnant rats and their fetuses.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Birth Weight; Dose-Response Relationship | 1993 |
Cyclic guanosine 3',5' monophosphate concentrations in pre-eclampsia: effects of hydralazine.
Topics: Adult; Arginine; Birth Weight; Blood Pressure; Cyclic GMP; Female; Humans; Hydralazine; Nitric Oxide | 1996 |
Evaluation of a program of bed rest in the treatment of chronic hypertension in pregnancy.
Topics: Bed Rest; Birth Weight; Chronic Disease; Female; Fetal Death; Humans; Hydralazine; Hypertension; Inf | 1979 |
Outcome of pregnancies complicated by severe hypertension and delivered before 34 weeks; stepwise logistic regression analysis of prognostic factors.
Topics: Adult; Birth Weight; Cerebral Hemorrhage; Cesarean Section; Female; Fetal Growth Retardation; Gestat | 1989 |
Plasma prolactin concentrations and pregnancy-induced hypertension.
Topics: Adult; Apgar Score; Birth Weight; Circadian Rhythm; Female; Gestational Age; Humans; Hydralazine; Hy | 1985 |
Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester.
Topics: Administration, Oral; Antihypertensive Agents; Bed Rest; Birth Weight; Delivery, Obstetric; Diuretic | 1985 |
Diuretic-hypotensive therapy and fetal prognosis in toxaemia of pregnancy. 1. Fetal prognosis in 705 selected cases.
Topics: Acetazolamide; Ammonium Chloride; Antihypertensive Agents; Barbiturates; Birth Weight; Chlorothiazid | 1973 |
Active management of severe pre-eclampsia.
Topics: Adult; Animals; Apgar Score; Birth Weight; Delivery, Obstetric; Diazepam; Female; Fetal Death; Human | 1973 |